Rupatadine
Top View
- Population Pharmacokinetic Modelling of Rupatadine Solution in 6–11 Year Olds and Optimisation of the Experimental Design in Younger Children
- Connecting the Dots with EDS, POTS, MCAS, GI, Neurological and Physiotherapy in Managing Pain in EDS
- Unsuspected Polymorphic Metabolism of Rupatadine Via Its Primary
- (Therapeutic Products) Regulations 2015
- Chemical Structure-Related Drug-Like Criteria of Global Approved Drugs
- A Randomized, Double-Blind, Parallel-Group Study, Comparing the Efficacy and Safety of Rupatadine (20 And
- Mebhydrolin Napadisylate
- Rupatadine 20 Mg and 40 Mg Are Effective in Reducing the Symptoms of Chronic Cold Urticaria
- Use of Combinations Comprising a Corticosteroid and a Pyrimidopyrimidine in the Treatment of Inflammatory Diseases
- Rupatadine 10 and 20 Mg Are Effective
- Use of Phenotypically Poor Metabolizer Individual Donor
- Pharmaabkommen A1 E
- NVA237 / Glycopyrronium Bromide Multinational, Multi-Database Cohort
- A Direct Comparison of Efficacy Between Desloratadine and Rupatadine in Seasonal Allergic Rhinoconjunctivitis: a Randomized, Double-Blind, Placebo-Controlled Study
- H1‐Antihistamines for Primary Mast Cell Activation Syndromes (MCAS): a Systematic Review
- Rupatadine Oral Solution for 2–5-Year-Old Children with Allergic Rhinitis: a Safety, Open-Label, Prospective Study
- An Inventory of Medicinal Products Causing Skin Rash: Clinical and Regulatory Lessons
- 77 Drug Therapy for Symptoms Associated with Anxiety in Adult Palliative Care Patients